Inovio Pharmaceuticals Inc vs Seagate Technology Holdings PLC — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while Seagate Technology Holdings PLC trades at $905 (market cap $181.56B). The key difference: Seagate Technology Holdings PLC is far larger — about 2033.8× Inovio Pharmaceuticals Inc's market cap, and Seagate Technology Holdings PLC pays a 0.37% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | STX | |
|---|---|---|
Market Cap | $89.27M | $181.56B |
Sector | Health | Technology |
52-Week High | $2.87 | $1.09K |
52-Week Low | $1.05 | $146.59 |
Enterprise Value | $60.28M | $184.59B |
Dividend Yield | — | 0.37% |
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
Seagate Technology (STX) trades at $891.23, up 13.25% over the past 24 hours, with strong recent earnings beats and bullish analyst sentiment. The stock shows bearish technical signals but benefits from robust profitability metrics including a 21.6% net income margin and 96.27% ROE. Recent news highlights AI-driven storage demand as a key growth catalyst, with the company set to report Q2 2026 earnings on July 28, 2026.
Outlook remains positive due to AI infrastructure expansion and consistent earnings outperformance, though high valuation ratios and negative shareholder equity pose risks. Analyst consensus price target of $987.86 suggests upside potential, but investors should monitor debt levels and competitive pressures in the storage sector.
Trailing returns across standard periods
Latest headlines on both assets
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →